Marina Biotech gets decision to grant Japanese Patent for SMARTICLES nucleic acid delivery technology
The claims of this National Stage Application cover delivery technology based on Marina’s proprietary SMARTICLES amphoteric liposomes and directly support the clinical programs of the company’s licensees ProNAi
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.